Paul Mullen Chosen to Lead Microbot Medical’s U.S. Sales Force

Microbot Medical Inc. has appointed Paul Mullen to the newly created sales vice president role. He is charged with building out the company’s sales strategy and infrastructure to ensure its LIBERTY Endovascular Robotic System is successfully launched upon U.S. Food and Drug Administration (FDA) clearance, expected in the second quarter.

Mullen has an extensive track record in sales, market development and management, and will lead the Microbot Medical’s U.S. commercial sales. He reports directly to CEO/Chairman/President Harel Gadot.

Mullen has extensive market experience with medical devices for endovascular diseases, and has successfully launched innovative technologies and driven efficiencies across expansive sales territories. Before joining Microbot Medical, Mullen was sales director at Inari Medical (acquired by Stryker earlier this year for $4.94 billion), a provider of medical products designed for the endovascular treatment of deep vein thrombosis (DVT) and pulmonary embolisms (PE). Mullen was integral in launching multiple breakthrough devices while at Inari, including the first FDA-cleared thrombectomy device for pulmonary embolism. Most recently, he was tasked with launching two new devices to treat chronic venous disease which affects more than 1 million U.S. patients.

Prior to Inari Medical, Mullen was at Philips Volcano, the endovascular division of the medical company that specializes in image-guided therapy products, where he launched multiple new technologies and generated coronary and peripheral atherectomy product line sales. Before that, he was the Southeast regional sales manager at LeMaitre Vascular Inc., a provider of peripheral vascular surgical products; while there, he managed direct sales representatives focused on vascular surgeons, C-suites, and value analysis committees.

“The appointment of Paul, with his extensive commercial experience in the endovascular space, is another cornerstone in the efforts to build our commercial infrastructure in anticipation of FDA clearance during Q2 of this year,” Gadot said. “Paul has an impressive track record of launching new products and developing new markets in the endovascular space. His demonstrated success and excellent leadership qualities are key attributes we prioritized in our search for a U.S. sales leader. I look forward to his contributions as we develop our sales strategy and execute on our business goals.”

Microbot Medical Inc. is a pre-commercial stage medical technology company striving to redefine endovascular robotics by developing the world’s first single-use, fully disposable endovascular robotic system. Microbot Medical aims to improve care for millions of patients and providers globally by eliminating barriers to access for advanced robotic endovascular technologies.